Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an "omics" approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Little evidence is available on circulating phosphatidylinositol and phosphatidylserine, which have been found to be higher in MASL(101, 102) or only in MASH (phosphatidylinositol).108”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“High levels of plasma ceramides are correlated with the severity of MASLD and reflect hepatic ceramide accumulation.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Plasma saturated/unsaturated fatty acid TAGs have been found to be elevated,102,103 and associated with IR11,104 in individuals with MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Patients with MASH have 20% higher ceramide concentrations compared to healthy individuals.100,102,104,117”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“A few studies have also investigated circulating lipidomic species in patients with advanced forms of MASH (F3), fibrosis, and cirrhosis, showing an increase in circulating levels of some ceramides (d18:1/20:0, d18:1/22:0, d18:1/23:0, d18:1/24:1, d18:1/24:0) and a decrease in hexosylceramide,115 some glucosylceramide (d18:1/24:1, d18:1/26:1, 18:1/26:0), SM, PC, LPC, and phosphatidylinositol94,102”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Self-citation
Cited by
Items 201–300 of 374
Kumari, D., Gautam, J., Sharma, V., Gupta, S. K., Sarkar, S., Jana, P., Singhal, V., Babele, P., Kamboj, P., Bajpai, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22051 · Cited by 29
“Lipotoxicity in the liver is linked to an increase in saturated TGs and a decrease in unsaturated TGs (containing PUFA) [106].”
BackgroundSelf-citationZhang, L., Du, Y., Li, Y., Wang, T., Pan, Y., Xue, X., Mu, X., Qiu, J., & Qian, Y. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136958 · Cited by 16
Liang, K., Gao, H., Gu, Y., Yang, S., Zhang, J., Li, J., Wang, Y., Wang, Y., & Li, Y. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.07.049 · Cited by 15
Vallée, D., Blanc, M., Lebeaupin, C., & Bailly‐Maitre, B. (2020) · médecine/sciences · doi:10.1051/medsci/2020008 · Cited by 20
Sydor, S., Sowa, J., Megger, D. A., Schlattjan, M., Jafoui, S., Wingerter, L., Carpinteiro, A., Baba, H. A., Bechmann, L. P., Sitek, B., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.03.002 · Cited by 15
Yang, Y., Huang, Z., Yang, Z., Qi, Y., Shi, H., Zhou, Y., Wang, F., & Yang, M. (2021) · PeerJ · doi:10.7717/peerj.11346 · Cited by 15
Bertran, L., Capellades, J., Abelló, S., Durán, J. M., Aguilar, C., Martínez, S., Sabench, F., Correig, X., Yanes, Ó., Auguet, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129789 · Cited by 15
“showed increased levels of PE 40:5, PE 40:6 and PI 36:1 in NASH subjects compared to the NL group [43].”
ResultSyed‐Abdul, M. M., Moore, M. P., Wheeler, A. A., Ganga, R., Diaz‐Arias, A. A., Petroski, G. F., Rector, R. S., Ibdah, J. A., & Parks, E. J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.09.018 · Cited by 16
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD
Thakral, N., Desalegn, H., Díaz, L. A., Cabrera, D., Loomba, R. S., Arrese, M. A., & Arab, J. P. (2024) · Seminars in Liver Disease · doi:10.1055/a-2364-2928 · Cited by 16
“75 However, lipid markers and their changes between disease states reported by independent studies were not concordant.”
Daniel, N., Barz, M. L., Mitchell, P. L., Varin, T. V., Bourdeau‐Julien, I., Farabos, D., Pilon, G., Gauthier, J., Garofalo, C., Kang, J. X., et al. (2022) · Function · doi:10.1093/function/zqac069 · Cited by 17
Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
Sharpe, M. C., Pyles, K. D., Hallcox, T., Kamm, D. R., Piechowski, M., Fisk, B. A., Albert, C. J., Carpenter, D. H., Ulmasov, B., Ford, D. A., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.02.004 · Cited by 13
“17,20,24,25 Increased omega oxidation products of arachidonate have been demonstrated in plasma lipidomic studies of NASH patients, suggesting increased disposal may reduce arachidonate availability for incorporation into phospholipid species.”
Das, S., & Bhatia, R. (2022) · Journal of Separation Science · doi:10.1002/jssc.202100996 · Cited by 13
Impaired hepatic lipid metabolism and biomarkers in fatty liver disease
Teixeira, F. S., Pimentel, L. L., Pintado, M., & Rodríguez-Alcalá, L. M. (2023) · Biochimie · doi:10.1016/j.biochi.2023.09.020 · Cited by 15
Yuan, L., Zhang, W., Fang, W., Zhuang, X., Gong, W., Xu, X., Li, Y., & Wang, X. Y. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c01351 · Cited by 13
Complications of lipodystrophy syndromes
Akıncı, G., Güler, M. Ç., & Akıncı, B. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104085 · Cited by 16
Wan, J., Li, J., Bandyopadhyay, S., Kelly, S. L., Xiang, Y., Zhang, J., Merrill, A. H., & Duan, J. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b05708 · Cited by 12
Self-citationZhu, N.-L., Huang, S., Zhang, Q., Zhao, Z., Qu, H. Y., Ning, M., Leng, Y., & Liu, J. (2021) · Metabolites · doi:10.3390/metabo11060374 · Cited by 13
“In recent lipidomics study of NAFLD, NASH and cirrhosis, a total of 48 lipid species were investigated in liver and plasma [29].”
BackgroundSmid, V., Dvořák, K., Stehnová, K., Strnad, H., Rubert, J., Stritesky, J., Staňková, B., Stranska-Zachariasova, M., Hajšlová, J., Brůha, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417226 · Cited by 11
Zhang, J., & Chen, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116701 · Cited by 16
Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease
Li, J., Zhao, Y., Huang, C., Chen, Z., Shi, X., Li, L., Chen, Z., & Li, X. (2019) · Endocrine Connections · doi:10.1530/ec-19-0023 · Cited by 15
Gautam, J., Kumari, D., Aggarwal, H., Gupta, S. K., Kasarla, S. S., Sarkar, S., Priya, M. R. K., Kamboj, P., Kumar, Y., & Dikshit, M. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159348 · Cited by 11
Self-citationIntroduction to Thematic Minireview Series: Novel Bioactive Sphingolipids
Merrill, A. H., & Carman, G. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.663708 · Cited by 13
“Elevations in these bioactive compounds have also been found in diabetes (31), non-alcoholic steatohepatitis (32), and when serine biosynthesis is defective (33), and can be envisioned for other conditions where metabolic changes or diet alter the amounts.”
BackgroundSelf-citationMaciejewska, D., Palma, J., Dec, K., Skonieczna‐Żydecka, K., Gutowska, I., Szczuko, M., Jakubczyk, K., & Stachowska, E. (2019) · Diagnostics · doi:10.3390/diagnostics9040197 · Cited by 14
“Currently, researchers are searching for non-invasive lipid biomarkers of the metabolic symptoms of many metabolic diseases [1,2].”
BackgroundEvolução da doença hepática gordurosa não alcoólica: revisão de literatura
Miquelito, J. T., & de Siqueira, E. C. (2022) · Revista de Saúde · doi:10.21727/rs.v13i1.2915 · Cited by 11
Huneault, H. E., Chen, C., Cohen, C. C., Liu, X., Jarrell, Z. R., He, Z., DeSantos, K., Welsh, J. A., Maner-Smith, K. M., Ortlund, E. A., et al. (2024) · Metabolites · doi:10.3390/metabo14040191 · Cited by 11
“However, a recent lipidomics study in adults highlighted that ChE, among other plasma lipid classes, helped distinguish those with healthy livers from those with steatosis and MASH [74].”
BackgroundMerrill, A. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020650 · Cited by 13
“1-Deoxysphingolipids have been associated with numerous pathologic conditions in addition to the original neuropathies [83], including diabetes [89,90], liver disease [91,92], and docetaxel neurotoxicity [93].”
Self-citationTang, N., Ji, L., Shi, X., Xiong, Y., Xiong, X., Zhao, H., Song, H., Wang, J., Zhang, L., You, S., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040502 · Cited by 12
“Research shows that decreased glycolytic/TCA cycle metabolites are associated with cirrhosis; we can infer that the down-regulation of glycolytic/TCA cycle metabolites may be linked to liver injury [29].”
BackgroundGoon, D. E., Rahim, S. A., Sakri, A. H. M., Mazlan, M., Tan, J. K., Aziz, M. A., Noor, N. M., Ibrahim, E., & Kadir, S. H. S. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00454-9 · Cited by 13
McCaffrey, J. M., & Ibdah, J. A. (2025) · Nutrients · doi:10.3390/nu17182972 · Cited by 19
“One study compared the lipid content of liver and plasma samples from patients grouped as healthy, simple steatosis, NASH, or cirrhosis [172].”
Lipid metabolism and metabolites: emerging roles in systemic physiology and metabolic diseases
Xu, J., Lu, D., & Huang, X. (2026) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2026.01.006 · Cited by 15
Mazi, T. A., Borkowski, K., Fiehn, O., Bowlus, C. L., Sarkar, S., Matsukuma, K. E., Ali, M. R., Kieffer, D. A., Wan, Y. Y., Stanhope, K. L., et al. (2022) · Metabolites · doi:10.3390/metabo12020192 · Cited by 11
Duparc, T., Gore, E., Combes, G., Beuzelin, D., Silva, J. P. D., Bouguetoch, V., Marqués, M.-A., Velazquez, A., Viguerie, N., Tavernier, G., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175623 · Cited by 15
“R–KO mice, including 5, 12-, and 15-HETE, have been reported as lipid signatures of MASLD progression (36, 37).”
Angelini, G., Russo, S. L. M. L., Carli, F., Infelise, P., Panunzi, S., BERTUZZI, A., Caristo, M. E., Lembo, E., Calce, R., Bornstein, S. R., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202402108r · Cited by 13
“24,25 Accordingly, plasma triglycerides, lysophosphatidyl-cholines and other phosphatidylcholines were significantly lower in rats fed an HFD, and DC12 than HFD alone (Figures 4 and S2).”
Mouskeftara, T., Kalopitas, G., Liapikos, T., Arvanitakis, K., Theocharidou, E., Germanidis, G. S., & Gika, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313067 · Cited by 11
Bechyňská, K., Kosek, V., Fenclová, M., Muchová, L., Smid, V., Šuk, J., Chalupský, K., Sticová, E., Hůrková, K., Hajšlová, J., et al. (2021) · Biomolecules · doi:10.3390/biom11111723 · Cited by 11
“Despite several limitations of the present study hindering more accurate interpretation of our observations (firstly, dietary intervention used in our study did not result in development of significant inflammatory changes in the liver tissue, most likely due to a relatively short period of intervention, and secondly,…”
BackgroundInfluentialLiu, C., Zheng, S., Wang, S., Wu, D., Jiang, W., Zeng, Q., Wei, Y., Zhang, Y., & Tang, H. (2021) · Diagnostics · doi:10.3390/diagnostics12061412 · Cited by 10
Barboza, T. K., Susta, L., Linden, A. Z., Gardhouse, S. M., & Beaufrère, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0274060 · Cited by 12
“…used lipid biomarkers such as plasma non-esterified fatty acids (NEFA), ketones, triglycerides, lipoproteins [5, 14, 15], and other metabolites at a larger scale through metabolomics/lipidomics [16–20] may help with screening, diagnosing, and monitoring this disease in a non-invasive manner.”
Sphingolipidomics in Translational Sepsis Research–Biomedical Considerations and Perspectives
Claus, R. A., & Gräler, M. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.616578 · Cited by 15
Monirujjaman, M., Bathe, O. F., & Mazurak, V. C. (2022) · Cancers · doi:10.3390/cancers14225703 · Cited by 10
Yalcin, E. B., Tong, M., Cao, K., Huang, C., & de la Monte, S. M. (2023) · European Journal of Biology and Biotechnology · doi:10.24018/ejbio.2023.4.1.135 · Cited by 10
Hada, N., Katsume, A., Kenichi, K., Endo, C., Horiba, N., & Sudoh, M. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1094 · Cited by 11
McDonald, J. G., Ivanova, P. T., & Brown, H. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-63438-2.00002-x · Cited by 11
Self-citationGuo, W., Wu, D., Dao, M. C., Li, L., Lewis, E. D., Ortega, E. F., Eom, H., Thomas, M., Nikolova‐Karakashian, M., Meydani, M., et al. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa259 · Cited by 10
“Plasma ceramides have been identified as novel biomarkers of NAFLD in humans (41).”
BackgroundThe diagnostic conundrum in non-alcoholic fatty liver disease
Rosato, V., Masarone, M., Aglitti, A., & Persico, M. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00018 · Cited by 10
“Circulating oxidized fatty acids and products of arachidonic acid metabolism associated with NASH were identified by a lipidomic approach [141].”
BackgroundLuckhoff, H. K., Kruger, F. C., & Kotze, M. J. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i9.1192 · Cited by 10
Weyler, J., Verrijken, A., Hornemann, T., Vonghia, L., Dirinck, E. L., von Eckardstein, A., Vanwolleghem, T., Michielsen, P. P., PEIFFER, F. W., Driessen, A. L. C., et al. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01612-7 · Cited by 10
Migni, A., Bartolini, D., Marcantonini, G., Sardella, R., Rende, M., Tognoloni, A., Ceccarini, M. R., & Galli, F. (2025) · Journal of Pineal Research · doi:10.1111/jpi.70047 · Cited by 8
Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD
Migni, A., Bartolini, D., Ceccarini, M. R., Galli, C., Cavaliere, G., Garetto, S., Lucci, J., & Galli, F. (2026) · Progress in Lipid Research · doi:10.1016/j.plipres.2026.101380 · Cited by 10
Inferring secretory and metabolic pathway activity from omic data with secCellFie
Masson, H. O., Samoudi, M., Robinson, C. M., Kuo, C.-C., Weiß, L., Shams‐Ud‐Doha, K., Campos, A. R., Tejwani, V., Dahodwala, H., Ménard, P., et al. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2023.12.006 · Cited by 9
Sourianarayanane, A., Brydges, C. R., & McCullough, A. J. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102402 · Cited by 9
Molecular phenomics of a high-calorie diet-induced porcine model of prepubertal obesity
Jové, M., Tibau, J., Serrano, J. C. E., Berdún, R., Rodríguez-Palmero, M., Font‐i‐Furnols, M., Cassanyé, A., Rodríguez-Mortera, R., Sol, J., Rassendren, H., et al. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108393 · Cited by 8
Kalopitas, G., Mouskeftara, T., Liapikos, T., Arvanitakis, K., Ioannidis, A., Malandris, K., Theocharidou, E., Chourdakis, M., Sinakos, E., Gika, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612717 · Cited by 7
Update on lipid species and paediatric nonalcoholic fatty liver disease
Mann, J. P., Feldstein, A. E., & Nobili, V. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000346 · Cited by 10
Castillo-Castro, C., Martagón, A. J., Ortíz-López, R., Garrido-Trevino, L., Villegas-Albo, M., & Bosques‐Padilla, F. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1494 · Cited by 10
Hu, C., Li, X., Sui, Y., Chen, Y., Zhao, Y., Yang, Y., Zhou, Q. Y., Ni, H., Sun, L., Gan, W.-J., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00432-x · Cited by 8
“Lipidomic study also revealed distinct lipid profile in NASH, among which phospholipid was also upregulated in the serum [22].”
BackgroundKhan, A., & Hornemann, T. (2017) · EXCLI journal · doi:10.17179/excli2017-171 · Cited by 8
“, 2014), non-alcoholic steatohepatitis (Gorden et al., 2015), and defects in serine biosynthesis (Esaki et al.”
BackgroundKenwood, B. M., & Merrill, A. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10024-0 · Cited by 7
Self-citationMigni, A., Bartolini, D., Varfaj, I., Moscardini, I. F., Sardella, R., Garetto, S., Lucci, J., & Galli, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118068 · Cited by 6
Wu, H.-C., Hsieh, Y.-R., Wang, W., Chang, C.-W., Chang, I., Chen, C., Chang, C., Chang, C., Kao, W., & Huang, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113730 · Cited by 8
“However, our study showed a clear decrease in CE (20:1) levels in the NASH F2–4 group, which is consistent with the finding of a previous study in which specific CE signatures were lower in cases of NASH versus cases of steatosis [39].”
BackgroundResultQi, Z., Le, S., Cheng, R., Du, X., Zhao, C., Zhang, Z., Zhang, X., Feng, L., Schumann, M., Mao, L., et al. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003388 · Cited by 8
“It has been widely reported that altered PC metabolism is involved in liver fat accumulation (35,36).”
BackgroundCellular Interactions in the Human Fatty Liver
Sovaila, S., Silvia Sovaila, 2. P. R. S., Purcărea, A., Gheonea, D. I., Ionescu, S. O., & Ciurea, T. (2019) · Journal of Medicine and Life · doi:10.25122/jml-2019-1010 · Cited by 7
“NASH pathogenesis is thought to be related to potentially toxic lipid moieties like saturated fatty acids (SFA), diacylglycerols [3], ceramides and sphingolipids [4-6].”
BackgroundIruarrizaga‐Lejarreta, M., Bril, F., Noureddin, M., Ortiz, P., Lu, S. C.-L., Mato, J. M., & Alonso, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_16 · Cited by 9
Choudhary, K. S., Fahy, E., Coakley, K. L., Sud, M., Maurya, M. R., & Subramaniam, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.20.391912 · Cited by 6
“Case study 1 (ST000915): A nonalcoholic fatty liver disease (NAFLD) biomarker study This was a lipidomics study dealing with detecting lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in patients at different stages of Fatty Liver Disease.”
MethodSelf-citationHIF-1α Regulates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
Liu, Q., Liu, H., Yi, Z., Yang, Z., & Wen, S. (2025) · Digestion · doi:10.1159/000548503 · Cited by 5
Qin, L., Zhao, W. Z., Lin, Z., Bao, X., Li, R., Hao, Q., Yi, Z., Shen, Q., Jiang, H., Zhang, Y., et al. (2025) · Food & Function · doi:10.1039/d5fo02712h · Cited by 5
Wang, X., Zhao, M., Xia, G., Shi, H., Li, C., Shen, X., Rakariyatham, K., He, S., Liu, Z., & Zhou, D. (2024) · Food Frontiers · doi:10.1002/fft2.450 · Cited by 6
Self-citationBertran, L., Capellades, J., Abelló, S., & Richart, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318557 · Cited by 5
“On the other hand, Gorden et al. in 2015, performing the same analysis, reported decreased levels of LPE and sphingomyelins, and increased levels of PE and ceramides in 20 MASH subjects compared to 17 individuals with SS [30].”
Yu, Z., Wang, S., Hou, H., Ma, L., & Zhu, Y. (2020) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201900451 · Cited by 7
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 9
“Metabolomic and lipidomic approaches comparing liver and plasma of patients with steatosis, NASH, and cirrhosis has been utilized to identify biomarkers for diagnosis and prognosis (Aranha et al., 2008; Ferslew et al., 2015; Gorden et al., 2015; Mouzaki et al., 2016; Puri et al., 2018; Masoodi et al., 2021).”
MethodLu, Y., Fang, J., Ong, C. N., Chen, S., Li, N., Cui, L., Huang, C., Ling, Q., Chia, S. E., & Chen, M. (2016) · Metabolomics · doi:10.1007/s11306-016-1148-9 · Cited by 6
Tavakoli, T., Zarban, A., Hooshyar, R., Salmani, F., & Tajik, H. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1784953 · Cited by 5
“NAFLD may also be diagnosed during abdominal surgery, abdominal distension or liver function tests (Gorden et al. 2015).”
BackgroundRosso, N., Stephenson, A. M., Giraudi, P. J., & Tiribelli, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4723 · Cited by 5
Lipid mass spectrometry: A path traveled for 50 years
Murphy, R. C. (2020) · Journal of Mass Spectrometry · doi:10.1002/jms.4492 · Cited by 5
“out in clinical study organized by the LIPID MAPS consortium into nonalcoholic steatohepatitis (NASH) with over 80 subjects participating.(51) Analysis of neutral lipids revealed that several multiply unsatu-”
MethodSelf-citationHuang, Y., Chan, H., Khoo, J.-Y., Chan, M.-L., Bender, D. A., Ponnusamy, V. K., Belaidi, A. A., & Ke, L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106104 · Cited by 4
Effects of Tinospora cordifolia (giloy) on metabolic syndrome components: a mechanistic review
Mansouri, M., Imenshahidi, M., Rameshrad, M., & Hosseinzadeh, H. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03642-2 · Cited by 8
“Furthermore, lipotox-icity in the liver is related to elevated saturated TGs and decreased unsaturated TGs (Gorden et al. 2015).”
Transcriptomic and lipidomic analysis of aging-associated inflammatory signature in mouse liver
Ishihara, T., Tsugawa, H., Iwanami, S., Chang, J.-C., Minoda, A., & Arita, M. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00377-2 · Cited by 6
“In contrast, lipidomic analyses using liver biopsies from patients with hepatic diseases such as steatosis and cirrhosis have identified lipid species associated with disease pathology [87].”
Liu, L., Niu, Y., Guo, Z., Wang, C., Liu, H., Yang, J. H., Gao, P., & Xiang, P. (2025) · Environmental Chemistry and Ecotoxicology · doi:10.1016/j.enceco.2025.10.014 · Cited by 4
Song, Q., Zhao, Z., Liu, H., Zhang, J., Wang, Z., Zhang, Y., Ma, G., & Ge, S. (2024) · PeerJ · doi:10.7717/peerj.17380 · Cited by 5
“Dysregulation of glycerophospholipids in liver is suggested as a potential key link in the mechanism of disease progression toward NASH in humans ( Gorden et al., 2015 ).”
Tao, Y., Chen, Y., Ren, J., Jiang, S., Zhang, S., Xu, H. G., & Li, Y. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.741173 · Cited by 4
Tillander, V., Holmer, M., Hagström, H., Petersson, S., Brismar, T. B., Stal, P. I., & Lindqvist, C. (2024) · British Journal Of Nutrition · doi:10.1017/s0007114524001673 · Cited by 5
“However, common findings in studies where the hepatic lipidome has been investigated in subjects with steatosis or different stages of NAFLD are increased alterations in the hepatic content of long-chain PUFA (43 – 47) .”
BackgroundHelmy, A. S., Sherif, N. M., Ghanem, H. Z., Ibrahim, N. A., Gendy, A. E. G. E., Hussein, N. S., & Abdel-Hamid, A.-H. Z. (2019) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2019.s109 · Cited by 5
“Advanced diagnostic approach to avoid the requirements for invasive procedures is demanded for novel management strategies for the growing epidemic NAFLD (Gorden et al., 2015).”
BackgroundElingaard-Larsen, L. O., Villumsen, S. O., Justesen, L., Thuesen, A. C. B., Kim, M. G., Ali, M., Danielsen, E. R., Legido‐Quigley, C., van Hall, G., Hansen, T. F., et al. (2023) · Nutrients · doi:10.3390/nu15071590 · Cited by 4
“Investigations of the liver lipidome have revealed that TGs and CEs are among the lipid subclasses showing the most differential levels across disease states from simple steatosis to cirrhosis [47].”
BackgroundMetGENE: gene-centric metabolomics information retrieval tool
Srinivasan, S., Maurya, M. R., Ramachandran, S., Fahy, E., & Subramaniam, S. (2022) · GigaScience · doi:10.1093/gigascience/giad089 · Cited by 2
Self-citationUnderstanding the Lipidome at the Systems Level with lipidomeRPreprint
Suvitaival, T., & Legido‐Quigley, C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.16.994061 · Cited by 4
Shin, G., Lee, H. M., Kim, N. Y., Yoo, S., Park, Y. S., Park, H. S., Ryu, D., Kim, K. P., & Kim, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.01.462722 · Cited by 3
Weiss, U., Mungo, E., Haß, M., Benning, D., Gurke, R., Hahnefeld, L., Dorochow, E., Schlaudraff, J., Schmid, T., Kuntschar, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910721 · Cited by 5
“In particular, several ceramide species (e.g., Cer16:0, Cer18:0, and Cer24:1) and sphingomyelins have been previously associated with cardiovascular complications and endothelial dysfunction [50–56], as well as MASLD pathology [56].”
BackgroundA microphysiological model of human MASLD reveals paradoxical response to resmetirom
Hellen, D. J., Ungerleider, J. L., Tevonian, E. N., Sphabmixay, P., Roy, P., Meimetis, N., Presutti, F., Williams, A. M., Ogi, R., Lewis, C. A., et al. (2026) · Communications Biology · doi:10.1038/s42003-025-09484-9 · Cited by 4
“5E, F); hampered response to insulin, with signi fi cant metabolic reprogramming, but likely not as immunologically reactive as late-stage 75,76 .”
Berry, K. A. Z., Garfield, A., Macias, E., Zarini, S., Bowen, S., Cree‐Green, M., Snell‐Bergeon, J. K., Bodkin, S. G., & Bergman, B. C. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag018 · Cited by 5
A protein‐lipid complex that detoxifies free fatty acids
Cui, S., & Ye, J. (2022) · BioEssays · doi:10.1002/bies.202200210 · Cited by 3
Zhou, N., Zheng, W., Peng, L., Gao, S., Shi, Y., Cao, M., Xu, Y., Sun, B., & Li, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad710 · Cited by 4
Björnson, E., Samaras, D., Levin, M. C., Bäckhed, F., Bergström, G. M. L., & Gummesson, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-73406-8 · Cited by 3
Wang, H., Bullert, A. J., Linahon, M. J., Dailey, M. E., Doorn, J. A., Klingelhutz, A. J., Ankrum, J. A., & Lehmler, H. (2025) · Toxicology · doi:10.1016/j.tox.2025.154120 · Cited by 4
Introduction and Overview of Lipidomic Strategies
Griffiths, W. J., & Wang, Y. (2017) · Neuromethods · doi:10.1007/978-1-4939-6946-3_1 · Cited by 3
Kralj, T., Khatri, R., Brouwer, K. R., Brouwer, K. L. R., & Creek, D. J. (2022) · FEBS Letters · doi:10.1002/1873-3468.14318 · Cited by 4
Extracellular Vesicles and Fatty Liver
Lu, X., Song, M., & Gao, N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1443-2_9 · Cited by 3
Zhou, Z., Wei, T., Zhong, J., Deng, Y., Hou, Y., Liu, W., Deng, Z., & Li, J. (2023) · Food & Function · doi:10.1039/d3fo02508j · Cited by 3
Semertzidis, A., Mouskeftara, T., Gika, H., Pousinis, P., Makedou, K., Goulas, A., Kountouras, J., & Pοlyzos, S. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133798 · Cited by 3
Zhang, B., Zhao, W., Song, D., & Lyu, X. (2024) · Food & Function · doi:10.1039/d4fo01123f · Cited by 3
Abozaid, Y. J., Ayada, I., van Kleef, L. A., Goulding, N., Williams-Nguyen, J. S., Kaplan, R. C., de Knegt, R. J., Wagenknecht, L. E., Palmer, N. D., Timpson, N. J., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.09.006 · Cited by 4
“19,20 Hence, this study aimed to investigate the cross-sectional association between an extensive array of circulating metabolites and SLD, as well as liver enzymes, using data from population-based cohort studies, which may help to elucidate the pathophysiological mechanisms of SLD and also for…”
Beaufrère, H., Sosa-Higareda, M., & Ammersbach, M. (2025) · American Journal of Veterinary Research · doi:10.2460/ajvr.24.10.0316 · Cited by 3
Metadata
- Authors
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., Duan, J., Sullards, M. C., Leiker, T. J., Barkley, R. M., Quehenberger, O., Armando, A. M., Milne, S. B., Mathews, T. P., Armstrong, M. D., Li, C., Melvin, W. V., Clements, R. H., Washington, M. K., Mendonsa, A. M., Witztum, J. L., Guan, Z., Glass, C. K., Murphy, R. C., Dennis, E. A., Merrill, A. H., Russell, D. W., Subramaniam, S., & Brown, H. A.
- Affiliations
- Vanderbilt University Medical Center (US)
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Georgia Institute of Technology (US)
- University of Colorado Denver (US)
- Duke Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Subramaniam, Shankar
- Brown, H.Alex
- ORCID
- Fahy, Eoin
- Maurya, Mano R.
- Gupta, Shakti
- Spann, Nathanael J.
- McDonald, Jeffrey G.
- Duan, Jingjing
- Barkley, Robert M.
- Quehenberger, Oswald
- Armando, Aaron M.
- Milne, Stephen B.
- Mathews, Thomas P.
- Washington, M.Kay
- Witztum, Joseph L.
- Guan, Ziqiang
- Glass, Christopher K.
- Murphy, Robert C.
- Dennis, Edward A.
- Merrill, Alfred H.
- Russell, David W.
- Subramaniam, Shankar
- Brown, H.Alex
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 56
- Issue
- 3
- Pages
- 722-736
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4340319
- OpenAlex
- W2134541386
- Cited by
- 372
- References
- 73
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 38 · 2023: 34 · 2022: 34 · 2021: 56 · 2020: 42 · 2019: 32 · 2018: 25 · 2017: 20 · 2016: 21 · 2015: 11
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2040 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL106579)
- National Institute of Mental Health (T32MH093366)
- National Institute of General Medical Sciences (U54GM069338, R24GM107784, GM U54 069338)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK074868, P30DK058404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, steatosis, disease progression, lipidomics, plasma metabolites, biomarkers, glycerophospholipids, sphingolipids, sterols, liver biopsy, diagnostic signature, NAFLD staging
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Polymorphism, Single Nucleotide, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.